For sale India Nexavar supply India Nexavar price 15101509702

Trade name: Indian Nexavar Price USD/box Contact number
Generic name Sorafenib
Indications: Sorafenib has been approved for the treatment of advanced renal cell carcinoma (the most common type of kidney cancer) ). In addition, various clinical trials using sorafenib to treat various other cancers are currently ongoing around the world.
Note: It is recommended to check blood pressure once a week during the first week of sorafenib treatment. Because sorafenib can increase the risk of bleeding in patients, patients who are concurrently treated with warfarin should undergo relevant examinations regularly. Patients with a tendency of active bleeding (such as gastrointestinal bleeding) should use sorafenib with caution. It has been reported that Sorafenib may cause myelosuppression (such as neutropenia and thrombocytopenia). Therefore, patients who have undergone myelosuppressive therapy (including radiotherapy and chemotherapy) should not use Sorafenib. Caution should be exercised when taking fenib. Patients with active infections (including fungal infections or viral infections) should receive relevant treatment before using sorafenib. Patients who have been infected with herpes viruses such as herpes zoster, herpes simplex, or have a history of other viral infections may relapse after
chemotherapy. Patients should not undergo intramuscular injection while taking sorafenib. This is mainly because sorafenib may induce thrombocytopenia, making patients prone to bleeding, bruises or hematomas.
Based on the results of animal experiments and its mechanism of action of sorafenib, this drug is included in the risk classification category for use during pregnancy. Therefore, pregnant women should take contraceptive measures while taking sorafenib. If they become pregnant while taking the drug, , doctors should clearly inform patients of the dangers of this drug to the fetus. It is best not to breastfeed while taking sorafenib. The safety and effectiveness of sorafenib in pediatric patients have not been established. Sorafenib should be used with caution in patients with liver disease, jaundice or renal disease (<3/).
Adverse Reactions:
Common adverse events caused by sorafenib include rash, diarrhea, increased blood pressure, and redness, pain, swelling, or blisters on the palms or soles of the feet. In clinical trials, the most common treatment-related adverse events were diarrhea, rash/scaling, fatigue, skin reactions of the hands and feet, alopecia, nausea, vomiting, pruritus, hypertension, and decreased appetite. In sorafenib-treated patients, the number of grade 3 and grade 3 adverse events accounted for 3 and 3 of the total adverse events, respectively, compared with 3 and 3, respectively, in placebo-treated patients.
Dosage:
Sorafenib is a red, film-coated tablet, and the strength is per tablet. The recommended dose of sorafenib for the treatment of renal cell carcinoma is three times a day and should not be taken with food (it should be taken before or after eating). The drug manufacturer recommends that the drug be used long-term unless the efficacy of sorafenib decreases or patients cannot tolerate its toxic effects. If the patient experiences adverse drug reactions, the dosage of sorafenib can be reduced to once a day or every other day.
Medication Tips:
Patients should carefully read the product instructions and patient instructions before taking the medication. Patients should be informed that they must use effective contraception while taking the drug and must wait at least 10 weeks after stopping the drug before trying to become pregnant. Inform patients that it is best to take the medication on an empty stomach. If the patient forgets to take the medicine, there is no need to increase the dose the next time. When patients develop rash on their hands and feet while taking medication, they should contact their doctor promptly for corresponding treatment.
[Storage] Store in a sealed container at 3°C. Please keep the medicine out of the reach of children.
[Packaging] Tablets/Box
[Validity Period] Months